JPS6310736A - 免疫学的アジュバント - Google Patents
免疫学的アジュバントInfo
- Publication number
- JPS6310736A JPS6310736A JP62092947A JP9294787A JPS6310736A JP S6310736 A JPS6310736 A JP S6310736A JP 62092947 A JP62092947 A JP 62092947A JP 9294787 A JP9294787 A JP 9294787A JP S6310736 A JPS6310736 A JP S6310736A
- Authority
- JP
- Japan
- Prior art keywords
- adjuvant
- oil
- purified
- weight
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000568 immunological adjuvant Substances 0.000 title claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 57
- 239000000427 antigen Substances 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 239000002960 lipid emulsion Substances 0.000 claims description 24
- 239000003921 oil Substances 0.000 claims description 18
- 235000019198 oils Nutrition 0.000 claims description 17
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 15
- 239000000787 lecithin Substances 0.000 claims description 15
- 235000010445 lecithin Nutrition 0.000 claims description 15
- 229940067606 lecithin Drugs 0.000 claims description 15
- 229920005862 polyol Polymers 0.000 claims description 12
- 150000003077 polyols Chemical class 0.000 claims description 12
- 239000002158 endotoxin Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 5
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims description 5
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000010685 fatty oil Substances 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000020238 sunflower seed Nutrition 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 230000004043 responsiveness Effects 0.000 description 13
- 239000000839 emulsion Substances 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000193403 Clostridium Species 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 208000014770 Foot disease Diseases 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- -1 glycerin Chemical class 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241001573849 Enterobacillus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US852120 | 1986-04-15 | ||
| US06/852,120 US4806352A (en) | 1986-04-15 | 1986-04-15 | Immunological lipid emulsion adjuvant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6310736A true JPS6310736A (ja) | 1988-01-18 |
| JPH041728B2 JPH041728B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) | 1992-01-14 |
Family
ID=25312542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62092947A Granted JPS6310736A (ja) | 1986-04-15 | 1987-04-15 | 免疫学的アジュバント |
Country Status (9)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011092846A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社 ミキモト | 装身具用クラスプ |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916588A (en) * | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) * | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| CA1267087A (en) * | 1985-02-14 | 1990-03-27 | Nicolaas Visser | Synthetic immunogen |
| DE3601136A1 (de) * | 1986-01-16 | 1987-07-23 | Max Planck Gesellschaft | Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren |
| US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
| US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6054438A (en) * | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
| US5466714A (en) * | 1987-12-31 | 1995-11-14 | Research Foundation For Mental Health Hygiene, Inc. | Spermicidal and cytocidal fatty acid compositions |
| US4997851A (en) * | 1987-12-31 | 1991-03-05 | Isaacs Charles E | Antiviral and antibacterial activity of fatty acids and monoglycerides |
| US5434182A (en) * | 1987-12-31 | 1995-07-18 | Isaacs; Charles E. | Antibacterial fatty acid compositions |
| EP0324455A3 (en) * | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
| ES2019728A6 (es) * | 1988-09-23 | 1991-07-01 | Univ Southern California | Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma. |
| FI902821A7 (fi) * | 1989-06-12 | 1990-12-13 | Res Foundation For Mental Hygiene | Infektion leviämisen vähentäminen verenkäsittelylaitteistolla |
| DE4007315A1 (de) * | 1990-03-08 | 1991-09-12 | Behringwerke Ag | Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen |
| US5246707A (en) * | 1990-04-26 | 1993-09-21 | Haynes Duncan H | Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes |
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| HUT67762A (en) * | 1991-03-19 | 1995-04-28 | Cytrx Corp | Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof |
| US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
| AU668509B2 (en) * | 1991-04-19 | 1996-05-09 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| FR2702373B1 (fr) * | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
| BR9405957A (pt) * | 1993-03-23 | 1995-12-12 | Smithkline Beecham Biolog | Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil |
| ATE246513T1 (de) * | 1993-05-27 | 2003-08-15 | Entremed Inc | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten |
| US5718904A (en) * | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
| US5690942A (en) * | 1995-06-02 | 1997-11-25 | American Home Products Corporation | Adjuvants for viral vaccines |
| ATE386506T1 (de) * | 1995-10-17 | 2008-03-15 | Jagotec Ag | Verabreichung unlöslicher arzneistoffe |
| US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| US5849307A (en) * | 1997-03-26 | 1998-12-15 | The Picower Institute For Medical Research | Vaccine adjuvant |
| US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| CN1289091C (zh) * | 1998-02-11 | 2006-12-13 | Rtp药品公司 | 治疗炎症的药物组合物和相关用途 |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| JP2002516267A (ja) | 1998-05-29 | 2002-06-04 | アールティーピー・ファーマ・インコーポレーテッド | 熱的に保護された微粒子組成物及びその最終蒸気滅菌 |
| HK1040195B (zh) | 1998-08-19 | 2006-06-02 | Skyepharma Canada Inc. | 普鲁泊福的可注射水分散体 |
| GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
| AU767154B2 (en) | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
| EP2281833B1 (en) | 1999-04-09 | 2014-07-02 | Zoetis P&U LLC | Attenuated Pasteurellaceae bacterium having a mutation in a virulence gene |
| US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP2003509453A (ja) * | 1999-09-21 | 2003-03-11 | アールティーピー・ファーマ・インコーポレーテッド | 生物学的に活性な物質の、表面改質された粒状組成物 |
| AU2001256957B2 (en) | 2000-03-17 | 2005-08-25 | Pharmacia & Upjohn Company Llc | Salmonella vaccine materials and methods |
| WO2001077365A2 (en) | 2000-04-06 | 2001-10-18 | Pharmacia & Upjohn Company | Antimicrobial methods and materials |
| AU5711501A (en) | 2000-04-20 | 2001-11-07 | Rtp Pharma Inc | Improved water-insoluble drug particle process |
| US7323174B1 (en) | 2000-06-12 | 2008-01-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulation of immune response and methods based thereon |
| NZ525028A (en) | 2000-08-31 | 2005-07-29 | Skyepharma Canada Inc | Milled particles |
| US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
| JP2004509146A (ja) * | 2000-09-20 | 2004-03-25 | スカイファーマ・カナダ・インコーポレーテッド | 安定化フィブレート微粒子 |
| TWI288000B (en) * | 2001-02-22 | 2007-10-11 | Rtp Pharma Inc | Fibrate-statin combinations with reduced fed-fasted effects |
| FR2824279B1 (fr) * | 2001-05-04 | 2004-05-28 | Seppic Sa | Emulsion e/h concentree |
| GB0112126D0 (en) | 2001-05-18 | 2001-07-11 | Allergene Inc | Composition |
| FR2824269B1 (fr) * | 2001-09-03 | 2012-03-02 | Seppic Sa | Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras |
| US8193185B2 (en) | 2003-01-21 | 2012-06-05 | Novartis Vaccines And Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
| EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| GB0315323D0 (en) | 2003-07-01 | 2003-08-06 | Royal Veterinary College | Vaccine composition |
| US9023366B2 (en) | 2003-07-01 | 2015-05-05 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
| US20060210590A1 (en) | 2005-02-03 | 2006-09-21 | Alk-Abello A/S | Minor allergen control to increase safety of immunotherapy |
| ATE539079T1 (de) * | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| WO2007109810A2 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Methods for the preparation of imidazole-containing compounds |
| ES2388556T3 (es) * | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
| US9498493B2 (en) | 2007-09-27 | 2016-11-22 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| EP2296696B1 (en) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| AP2011005745A0 (en) | 2008-12-09 | 2011-06-30 | Gilead Sciences Inc | Modulators of toll-like receptors. |
| SI2569008T1 (sl) | 2010-05-14 | 2020-02-28 | Baxalta Incorporated | Himere OSPA in njihova uporaba v cepivih |
| WO2012010290A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| EP2462950A1 (en) | 2010-12-08 | 2012-06-13 | Neovacs | Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof |
| RU2013125147A (ru) | 2010-12-08 | 2015-01-20 | Неовакс | Сильно инактивированная иммуногенная вакцина, сохраняющая высокую иммуногенность, и способ ее изготовления |
| EP2694094B1 (en) | 2011-04-07 | 2017-08-16 | Neovacs | METHOD FOR TREATING IFNalpha RELATED CONDITIONS |
| EP2508197A1 (en) | 2011-04-07 | 2012-10-10 | Neovacs | Method for treating IFNalpha related conditions |
| ES2855474T3 (es) | 2011-10-06 | 2021-09-23 | Immunovaccine Technologies Inc | Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo |
| GB201200259D0 (en) | 2012-01-09 | 2012-02-22 | Ohlin Per M | Novel therapies |
| RU2015106742A (ru) | 2012-07-27 | 2016-09-20 | Бакстер Интернэшнл Инк. | Композиции, содержащие химерные молекулы ospa и способы их применения |
| WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
| US11725044B2 (en) | 2014-10-15 | 2023-08-15 | Xenothera | Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity |
| EP3801628A1 (en) | 2018-06-04 | 2021-04-14 | Apros Therapeutics, Inc. | Tlr7 peptide conjugates |
| KR20210027381A (ko) | 2018-07-02 | 2021-03-10 | 아유비스 리서치, 인코포레이티드 | 신규 면역조절 소분자 |
| EP3922255A1 (en) | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
| GB202009411D0 (en) | 2020-06-19 | 2020-08-05 | Prokarium Ltd | Autotransporter systems |
| CN112807426A (zh) * | 2021-01-26 | 2021-05-18 | 郭志文 | 一种基于动物疫苗的聚合物佐剂、制备方法及其应用 |
| EP4124342A1 (en) | 2021-07-28 | 2023-02-01 | Prokarium Limited | Cancer therapy with live attenuated bacteria |
| EP4399219A1 (en) | 2021-09-07 | 2024-07-17 | Université de Tours | Coronavirus fusion protein |
| GB202215134D0 (en) | 2022-10-13 | 2022-11-30 | Prokarium Ltd | Composition |
| GB202215576D0 (en) | 2022-10-21 | 2022-12-07 | Prokarium Ltd | Circuit |
| WO2025068413A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 18 variants |
| WO2025068401A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 15 variant |
| WO2025109155A1 (en) | 2023-11-24 | 2025-05-30 | Prokarium Limited | Interleukin variant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6072825A (ja) * | 1983-08-26 | 1985-04-24 | リビ イミユノケム リサ−チ，インコ−ポレイテイド | アジユバント応答を起こすか又は免疫応答を刺激することのできる組成物 |
| JPS6292948A (ja) * | 1985-10-19 | 1987-04-28 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1163470A (en) * | 1967-11-13 | 1969-09-04 | Cecil Arthur Clark | Improvements in or relating to Adjuvant Vaccines |
| CA943459A (en) * | 1968-12-16 | 1974-03-12 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| FR2160326B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) * | 1971-11-19 | 1975-02-07 | Anvar | |
| US4185090A (en) * | 1972-02-02 | 1980-01-22 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| GB1506563A (en) * | 1974-04-25 | 1978-04-05 | Williams J | Immunosuppressive agents |
| FR2313078A1 (fr) * | 1975-02-07 | 1976-12-31 | Anvar | Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention |
| US4338334A (en) * | 1977-12-29 | 1982-07-06 | Merck & Co., Inc. | 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases |
| US4307229A (en) * | 1979-11-07 | 1981-12-22 | Avraham Liav | 6,6'-Diesters of trehalose and process for the synthesis thereof |
| US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
-
1986
- 1986-04-15 US US06/852,120 patent/US4806352A/en not_active Expired - Lifetime
-
1987
- 1987-04-14 FR FR878705252A patent/FR2596990B1/fr not_active Expired - Lifetime
- 1987-04-14 FR FR878705271A patent/FR2598622B1/fr not_active Expired - Lifetime
- 1987-04-15 IT IT8747855A patent/IT1205819B/it active
- 1987-04-15 JP JP62092947A patent/JPS6310736A/ja active Granted
- 1987-04-15 GB GB8709023A patent/GB2189141B/en not_active Expired - Lifetime
- 1987-04-15 DE DE19873712767 patent/DE3712767A1/de active Granted
- 1987-04-15 ES ES8701112A patent/ES2005166A6/es not_active Expired
- 1987-04-15 AU AU71566/87A patent/AU574014B2/en not_active Ceased
- 1987-04-15 CA CA000534735A patent/CA1300503C/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6072825A (ja) * | 1983-08-26 | 1985-04-24 | リビ イミユノケム リサ−チ，インコ−ポレイテイド | アジユバント応答を起こすか又は免疫応答を刺激することのできる組成物 |
| JPS6292948A (ja) * | 1985-10-19 | 1987-04-28 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011092846A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社 ミキモト | 装身具用クラスプ |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2598622A1 (fr) | 1987-11-20 |
| DE3712767C2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) | 1991-06-27 |
| AU7156687A (en) | 1987-10-22 |
| US4806352A (en) | 1989-02-21 |
| GB2189141A (en) | 1987-10-21 |
| IT1205819B (it) | 1989-03-31 |
| GB2189141B (en) | 1990-07-25 |
| FR2598622B1 (fr) | 1990-05-11 |
| ES2005166A6 (es) | 1989-03-01 |
| DE3712767A1 (de) | 1987-10-22 |
| JPH041728B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) | 1992-01-14 |
| FR2596990A1 (fr) | 1987-10-16 |
| FR2596990B1 (fr) | 1990-12-07 |
| CA1300503C (en) | 1992-05-12 |
| GB8709023D0 (en) | 1987-05-20 |
| AU574014B2 (en) | 1988-06-23 |
| IT8747855A0 (it) | 1987-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6310736A (ja) | 免疫学的アジュバント | |
| JP2648305B2 (ja) | 多糖類ワクチン | |
| JP3814290B2 (ja) | 抗原用のアジュバントおよびその製法ならびに用途 | |
| JP5075317B2 (ja) | 莢膜性多糖類の可溶化および組合せワクチン | |
| Byars et al. | Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity | |
| AU710499B2 (en) | Adjuvants for viral vaccines | |
| JP2003502388A5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) | ||
| JP2003502388A (ja) | モノホスホリルリピドａの水性免疫学的アジュバント組成物 | |
| JP2000103745A (ja) | 処方物 | |
| US4395394A (en) | Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants | |
| JPH05507498A (ja) | 改良されたアジュバントおよびワクチン | |
| US6528058B1 (en) | Saponin adjuvant composition | |
| ES2388684T3 (es) | Adyuvantes de vacunas | |
| Harrison et al. | Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants | |
| US4310550A (en) | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants | |
| Johansson et al. | Identification of adjuvants that enhance the therapeutic antibody response to host IgE | |
| Edelman | An overview of adjuvant use | |
| Alexander et al. | Assessment of various adjuvants in sphaerophorus necrophorus toxoids | |
| Stewart-Tull | Symposium on immunological adjuvants | |
| Brey | Copolymer adjuvants | |
| CN1226173A (zh) | 脱乙酰壳多糖引起的免疫强化 | |
| JPS63258443A (ja) | 新規アルキルアルカノエートおよびその製法 | |
| BR112018016016B1 (pt) | Composição farmacêutica compreendendo um conjugado de um ou mais peptídeos cysab (33-40) (seq id no: 1) ligado à hemocianina do molusco keyhole limpet (klh), seu uso, seu método de produção, e ampola de vidro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080114 Year of fee payment: 16 |